StockData
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc. (ALNY) stock

ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$156.50−3.23 (-2.02%)

Close on Nov 17, 2026Market cap $20.96BP/E 8.1Yield –

Alnylam Pharmaceuticals cash

Cash and short-term investments held at the end of each period.

Alnylam Pharmaceuticals's cash was $3.59B at Sep 30, 2026. For fiscal 2025 it was $2.91B, up 8.2% from the year before. Over ten years it grew 10.9% a year on average. The highest annual figure on record is $2.91B in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.91B+8.2%
FY2024Dec 31, 2024$2.69B+10.7%
FY2023Dec 31, 2023$2.43B+12.1%
FY2022Dec 31, 2022$2.17B-8.6%
FY2021Dec 31, 2021$2.37B+29.4%
FY2020Dec 31, 2020$1.83B+20.4%
FY2019Dec 31, 2019$1.52B+40.6%
FY2018Dec 31, 2018$1.08B-35.9%
FY2017Dec 31, 2017$1.69B+173.7%
FY2016Dec 31, 2016$617.80M-40.0%
FY2015Dec 31, 2015$1.03B+70.9%
FY2014Dec 31, 2014$602.11M+144.9%
FY2013Dec 31, 2013$245.87M+100.2%
FY2012Dec 31, 2012$122.81M-16.1%
FY2011Dec 31, 2011$146.40M-37.2%
FY2010Dec 31, 2010$233.13M-17.2%
FY2009Dec 31, 2009$281.40M+46.7%
FY2008Dec 31, 2008$191.79M+82.4%
FY2007Dec 31, 2007$105.16M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$3.59B+31.7%
Q2 FY2026Jun 30, 2026$3.31B+15.8%
Q1 FY2026Mar 31, 2026$3.01B+14.6%
Q4 FY2025Dec 31, 2025$2.91B+8.2%
Q3 FY2025Sep 30, 2025$2.72B-1.7%
Q2 FY2025Jun 30, 2025$2.86B+9.3%
Q1 FY2025Mar 31, 2025$2.63B+11.2%
Q4 FY2024Dec 31, 2024$2.69B+10.7%
Q3 FY2024Sep 30, 2024$2.77B+15.7%
Q2 FY2024Jun 30, 2024$2.61B+28.8%
Q1 FY2024Mar 31, 2024$2.36B+15.4%
Q4 FY2023Dec 31, 2023$2.43B+12.1%
Q3 FY2023Sep 30, 2023$2.40B+6.8%
Q2 FY2023Jun 30, 2023$2.03B-2.4%
Q1 FY2023Mar 31, 2023$2.04B-7.4%
Q4 FY2022Dec 31, 2022$2.17B-8.6%
Q3 FY2022Sep 30, 2022$2.24B-0.6%
Q2 FY2022Jun 30, 2022$2.08B+12.6%
Q1 FY2022Mar 31, 2022$2.21B+33.6%
Q4 FY2021Dec 31, 2021$2.37B+29.4%
Q3 FY2021Sep 30, 2021$2.26B+26.9%
Q2 FY2021Jun 30, 2021$1.85B+0.5%
Q1 FY2021Mar 31, 2021$1.65B+26.7%
Q4 FY2020Dec 31, 2020$1.83B+20.4%
Q3 FY2020Sep 30, 2020$1.78B+3.2%
Q2 FY2020Jun 30, 2020$1.84B-4.5%
Q1 FY2020Mar 31, 2020$1.30B+4.8%
Q4 FY2019Dec 31, 2019$1.52B+40.6%
Q3 FY2019Sep 30, 2019$1.72B+40.9%
Q2 FY2019Jun 30, 2019$1.93B+34.2%
Q1 FY2019Mar 31, 2019$1.24B-20.6%
Q4 FY2018Dec 31, 2018$1.08B-35.9%
Q3 FY2018Sep 30, 2018$1.22B+28.8%
Q2 FY2018Jun 30, 2018$1.44B+55.5%
Q1 FY2018Mar 31, 2018$1.57B+181.5%
Q4 FY2017Dec 31, 2017$1.69B+173.7%
Q3 FY2017Sep 30, 2017$948.29M–
Q2 FY2017Jun 30, 2017$923.27M–
Q1 FY2017Mar 31, 2017$556.92M–
Q4 FY2016Dec 31, 2016$617.80M–

More Alnylam Pharmaceuticals figures

See a number that looks wrong?